BioSpace News Archive

Compugen Ltd. announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research annual meeting on April 5-11, 2024, in San Diego, California.

NanoMosaic, the multiplex and multi-omic quantification company, announced the expanded capabilities and availability of assays optimized on its Tessie™ system for use in gene therapy applications.

Geneos Therapeutics announced the upcoming presentation of two posters sharing new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, in patients with advanced hepatocellular carcinoma, at the 2024 American Association for Cancer Research Annual Meeting.

Innate Pharma SA announced the first patient was dosed in its Phase 1/2 multicenter trial, investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma.

Sosei Group Corporation announces that Formosa Pharmaceuticals, Inc. has received approval from the US Food & Drug Administration for clobetasol propionate ophthalmic suspension 0.05%, for the treatment of post-operative inflammation and pain following ocular surgery.

Medivir AB announces that the company will participate at the Swiss Nordic Bio conference on March 7, 2024.

Biomea Fusion, Inc. announced three poster presentations presenting long-term 26 week follow-up data from patients treated with BMF-219, enrolled in the escalation portion of the ongoing Phase II clinical study, at the 17th International Conference on Advanced Technologies & Treatments for Diabetes taking place in Florence, Italy from March 6-9, 2024.

Akeso Inc. announced the enrollment of the first patient in the registrational Phase III clinical study comparing Cadonilimab combined with chemotherapy versus Tislelizumab combined with chemotherapy in the first-line treatment for patients with PD-L1 negative non-small cell lung cancer.

Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies’ long-term development.

KalVista Pharmaceuticals, Inc. announced that its management will participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12th, 2024 at 9:20 a.m. ET in Miami, FL.